Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials

BACKGROUND: Cystic fibrosis (CF) is a life-threatening genetic disease, affecting around 10 500 people in the UK. Precision medicines have been developed to treat specific CF-gene mutations. The newest, elexacaftor/tezacaftor/ivacaftor (ELEX/TEZ/IVA), has been found to be highly effective in randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Keogh, Ruth H, Cosgriff, Rebecca, Andrinopoulou, Eleni-Rosalina, Brownlee, Keith G, Carr, Siobhán B, Diaz-Ordaz, Karla, Granger, Emily, Jewell, Nicholas P, Lewin, Alex, Leyrat, Clemence, Schlüter, Daniela K, van Smeden, Maarten, Szczesniak, Rhonda D, Connett, Gary J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Cystic Fibrosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940731/
https://www.ncbi.nlm.nih.gov/pubmed/34556554
http://dx.doi.org/10.1136/thoraxjnl-2020-216265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940731/
https://www.ncbi.nlm.nih.gov/pubmed/34556554
http://dx.doi.org/10.1136/thoraxjnl-2020-216265

Ejemplares similares